Thursday, October 31, 2013
A multi-institute team collaborating
with the FDA has determined why patients with
a form of severe hemophilia rarely develop neutralizing antibodies against factor
VIII replacement therapies. The team is also developing an
algorithm to predict the likelihood of antibody development against other
recombinant protein-based therapies.1 Based on the results, one of
the investigators has cofounded Haplomics Inc.
to develop new factor VIII replacement therapies.
Cain, C. SciBX 6(42); doi:10.1038/scibx.2013.1181
Published online Oct. 31, 2013
1. Pandey, G.S. et al. Nat.
Med.; published online Sept. 15, 2013; doi:10.1038/nm.3270
Contact: Zuben E. Sauna, Food
and Drug Administration, Bethesda, Md.
Contact: Tom E. Howard, VA Greater Los Angeles Healthcare
System, Los Angeles, Calif.
2. Viel, K.R. et
al. N. Engl. J. Med. 360, 1618-1627 (2009)
Biogen Idec Inc. (NASDAQ:BIIB),
The Children's Hospital of Philadelphia, Philadelphia, Pa.
Food and Drug Administration, Rockville, Md.
Haplomics Inc., Atlanta, Ga.
Keck School of Medicine of the University of Southern
National Hemophilia Foundation, New York, N.Y.
Novo Nordisk A/S (CSE:NVO;
NYSE:NVO), Bagsvaerd, Denmark
Perelman School of Medicine at the University of
University of California, Los Angeles David Geffen School
of Medicine, Los
VA Greater Los Angeles Healthcare System, Los Angeles, Calif.